Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: June 1, 2026 · This page is informational and does not constitute medical advice.
STEP-1 and SURMOUNT-1 DEXA substudies show modest BMD reductions consistent with the degree of weight loss. Large pharmacoepidemiologic studies of semaglutide and liraglutide have not detected increased fracture risk.
Clinical reference4 peer-reviewed sources
Editorial summary
Weight loss of any kind is associated with reductions in bone mineral density. The clinical question is whether GLP-1 receptor agonists produce additional skeletal effects beyond weight-loss expectation and whether the magnitude translates into fracture risk. DEXA substudies from STEP-1 and SURMOUNT-1 show modest BMD reductions consistent with the degree of weight loss¹², and large pharmacoepidemiologic studies have not detected increased fracture risk relative to comparators³.
Weight loss and bone density: the baseline relationship
BMD measured by DEXA correlates with body weight. Caloric-restriction weight loss in adults consistently produces approximately 1-2% reduction in hip and spine BMD per 10% body weight lost&sup4;. A patient losing 15% body weight on semaglutide should be expected to lose approximately 1.5-3.0% of hip BMD purely from weight-loss-related unloading.
STEP-1 and SURMOUNT-1 DEXA findings
The STEP-1 substudy showed approximately 1.6% reduction in total hip BMD and 1.2% reduction in lumbar spine BMD in semaglutide vs 0.4% and 0.2% in placebo¹. These differences are consistent with the weight-loss-related expectation.
The SURMOUNT-1 DEXA substudy showed approximately 1.5-2.5% reduction in hip BMD across dose levels, proportional to total weight loss².
Fracture pharmacoepidemiology
Database studies of patients on liraglutide or semaglutide for T2D have generally not detected increased fracture risk. A 2014 meta-analysis of GLP-1 RA trials reported no increase in fractures³.
The SELECT cardiovascular outcomes trial of semaglutide in 17,604 patients reported fracture as a serious adverse event at similar rates in semaglutide and placebo over 3 years. No specific fracture signal has been identified across SURPASS or SURMOUNT to date.
Higher-baseline-risk populations
Postmenopausal women, older adults, patients on chronic glucocorticoids, and patients with established osteoporosis carry higher baseline fracture risk. Pre-treatment DEXA, FRAX assessment, and management of osteoporosis with antiresorptives are reasonable before initiating GLP-1 in these patients.
Calcium (1,000-1,200 mg/day) and vitamin D (800-1,000 IU/day) supplementation is standard in older adults during any caloric-restriction weight loss. Resistance training mitigates BMD loss during weight reduction in randomized trials.
$99 on 6 months · $105 on 3 months · $109 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).
Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.
Pharmacies named on its plan pages:Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.
Trade-offs: compounded semaglutide is not FDA-approved and is not Wegovy or Ozempic. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
$119 on 6 months · $125 on 3 months · $129 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).
Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.
Pharmacies named on its plan pages:Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.
Trade-offs: compounded tirzepatide is not FDA-approved and is not Zepbound or Mounjaro. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
Some BMD loss occurs with any substantial weight loss. On semaglutide, the magnitude (1-2% hip BMD) is consistent with non-pharmacologic weight loss and has not translated into measurable fracture excess.
Should I get a DEXA before starting Wegovy?
Not routine. Reasonable in postmenopausal women, adults over 65, patients on chronic corticosteroids, and patients with prior fragility fracture or known osteoporosis.
How can I protect bones while losing weight?
Calcium 1,000-1,200 mg/day, vitamin D 800-1,000 IU/day, protein 1.2 g/kg/day or higher, and weight-bearing or resistance exercise. Treat established osteoporosis with appropriate antiresorptive therapy.
Is tirzepatide worse for bones than semaglutide?
Available data suggest similar weight-loss-proportional BMD changes for both. Greater absolute weight loss on tirzepatide may produce slightly greater absolute BMD reduction.
Do GLP-1 drugs cause osteoporosis?
GLP-1 receptor agonists do not appear to cause de novo osteoporosis. BMD changes appear attributable to weight loss itself rather than drug-specific mechanism.
References
Wilding JPH, Batterham RL, Calanna S, et al.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1).N Engl J Med. 2021;384(11):989-1002.PMID: 33567185
Jastreboff AM, Aronne LJ, Ahmad NN, et al.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).N Engl J Med. 2022;387(3):205-216.PMID: 35658024
Mabilleau G, Mieczkowska A, Chappard D.Use of glucagon-like peptide-1 receptor agonists and bone fractures: meta-analysis of randomized clinical trials.J Diabetes. 2014;6(3):260-266.PMID: 24164867
Hinton PS, Nigh P, Thyfault J.Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass.Bone. 2015;79:203-212.PMID: 26092649
Citations are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed. FDA links resolve to fda.gov. All citations were last verified 2026-05-11.